by Hannah Buckelew
On October 1, 2022, the Department of Pathology welcomes two new members to the Division of Molecular and Cellular Pathology, directed by Ralph Sanderson, Ph.D.
Ming He, M.D., Ph.D., joins the department as assistant professor from the University of California, San Diego, where he served as an Assistant Project Scientist in the Department of Medicine’s Division of Cardiology.
Daniel Tyrrell, Ph.D.Daniel Tyrrell, Ph.D., Assistant Professor, Molecular and Cellular Pathology, was recently awarded an R00 to study the increased risk of vascular disease in older adults. Tyrrell, who joined the department in August, had an active K99 grant funded at the University of Michigan by the National Institutes of Health, to study, “Cerebrovascular Mitochondrial Function in Aging and Ischemic Injury.”
This grant mechanism is designed to support rising faculty members, and is Tyrrell's first. The proposed research will examine mechanisms of why older adults are at increased risk of vascular disease.
"Current treatments for dementia are inadequate for people of all ages," Tyrrell says. “My proposed research will determine how mitochondria and inflammation in blood vessels in the brain enhance cognitive decline with the goal of improving treatment for dementia and related diseases in blood vessels of the brain.”
The UAB Department of Pathology was proud to pull together faculty, trainees, students and staff from across campus to celebrate the variety of research endeavors ongoing in the department in its 2022 Research Retreat.
The event took place Friday, September 23, at the Hill University Center. A total of 148 faculty, staff, and trainees, as well as some undergraduate and medical students, registered and took part in this year's event.
C. Ryan Miller, M.D., Ph.D., Vishnu Reddy Translational Research Endowed Professor and Division Director, Neuropathology, published a review article in the journal Neuro Oncology on September 19 with colleagues on EGFR, the epidermal growth factor receptor, arguing for its role in precision oncology treatment of glioblastoma (GBM), a currently untreatable form of brain cancer.
"EGFR, the Lazarus target for precision oncology in glioblastoma," is a review focused on a topic Miller wished to study for years, but received multiple rejections for grant applications on the topic before finally obtaining funding this January. 
Page 47 of 120